Summary
Acetazolamide has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Type 1 Diabetes would be drug repurposing rather than first-in-human development. This does not mean it is approved for Type 1 Diabetes. ClinicalTrials.gov lists 2 registered trials linking Acetazolamide to Type 1 Diabetes: 1 is currently recruiting; 1 has completed. The most advanced is Phase 2 (NCT06981234). It plans or enrolled 25 participants. Registration activity spans 2023 to 2024. The literature layer holds 1 publication for this pair: 1 clinical trial publication. The dated items are from 2009. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Type 1 Diabetes Mellitus ranks 324 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Essentially zero for established T1DM (honeymoon phase occurs in 50-60% after diagnosis but lasts 3-12 months then ends); the disease is permanent autoimmune destruction of beta cells.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 28.5 (trials 6.5, literature 2.0, tier 15, approved bonus 5.0) |
| Registered trials | 2 total: 1 recruiting, 0 active / not yet recruiting, 1 completed, 0 other |
| Linked publications | 1 (1 clinical trial publication) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
| Linked via biomarker / target | ANG |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT06981234 | Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial 2024 | recruiting | Phase 2 | 25 |
| NCT05473364 | Acetazolamide in Persons With Type 1 Diabetes - Dose Finding 2023 | completed | PHASE1, PHASE2 | 12 |
Published literature
- Clinical trial publication Changes in cerebral blood flow detected by SPECT in type 1 and type 2 diabetic patientsKáplár M, Paragh G, Erdei A et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2009 · PMID 19910437
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL, in this case via the biomarker or target ANG. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Acetazolamide approved for Type 1 Diabetes?
Acetazolamide has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Type 1 Diabetes would be drug repurposing rather than first-in-human development. This does not mean it is approved for Type 1 Diabetes. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Acetazolamide in clinical trials for Type 1 Diabetes?
ClinicalTrials.gov lists 2 registered trials linking Acetazolamide to Type 1 Diabetes: 1 is currently recruiting; 1 has completed. The most advanced is Phase 2 (NCT06981234). It plans or enrolled 25 participants. Registration activity spans 2023 to 2024.
What does the evidence show for Acetazolamide in Type 1 Diabetes?
Acetazolamide has 1 completed trial and 1 linked publication for Type 1 Diabetes. Completed trials may or may not have posted results; follow the NCT links to check. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL, in this case via the biomarker or target ANG. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.